Nab-paclitaxel Versus Sb-taxanes As First-Line Treatment in Advanced Ovarian Cancer

This trial compares nab-paclitaxel (albumin-bound paclitaxel) against standard taxane chemotherapy drugs as first-line treatment for advanced ovarian, fallopian tube, or primary peritoneal cancer (stage III or IV). All of these are typically treated with carboplatin plus a taxane drug, but different formulations vary in effectiveness and side effects. The study aims to find the better option. **You may be eligible if...** - You have been diagnosed with stage III or IV epithelial ovarian, fallopian tube, or peritoneal cancer, confirmed by biopsy or cytology - You have not previously received chemotherapy or pelvic radiation for this cancer - You are in good enough health (ECOG score 0–2) and expected to live at least 6 months - Your cancer is measurable on imaging - You are willing to attend regular clinic visits and agree to participate **You may NOT be eligible if...** - Your tumour is of low malignant potential (borderline) - You have had another cancer in the last 5 years (except treated cervical carcinoma in situ or skin cancer) - You have cancer spread to the brain, or significant nerve damage (peripheral neuropathy > grade 1) - You have severe heart disease, serious heart rhythm problems, or recent blood clots or stroke (within 6 months) - You have severe liver or kidney dysfunction - You are pregnant or breastfeeding - You are allergic to paclitaxel, albumin, or carboplatin Talk to your doctor to see if this trial is right for you.